Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss

NCT02941445 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication sitagliptin, combined with metformin, helps maintain weight loss in women with polycystic ovary syndrome after they have lost weight using another medication called liraglutide.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–50 · female only

Timeline Started 2015-10 · est. completion 2016-08

What this study is testing ClinicalTrials.gov NCT02941445 ↗

Description as written by the study sponsor.

Weight reduction is the most important treatment target in obese women with polycystic ovary syndrome (PCOS), yet it is usually hardly achievable with lifestyle intervention alone. Glucagon-like peptide 1 (GLP-1) receptor agonist (RA) liraglutide was recently approved as an anti-obesity drug but with some limitations, which include high cost and the lack of long-term efficacy and safety data regarding weight reduction. In addition, weight loss achieved with liraglutide is often non-sustainable after treatment cessation. Although DPP-4 inhibitors are weight neutral, they reduced weight regain in animals previously treated with GLP-1 RAs if they were switched to DPP-4 inhibitor rather than placebo. The aim is to evaluate whether DPP-4 inhibitor sitagliptin in combination with metformin reduce body weight regain more effectively than metformin alone in obese PCOS who had been previously treated with liraglutide.

Treatments tested

sitagliptin and metformin also known as Janumet Drug
Metformin also known as Glucophage Drug

Main thing measured	Change in body weight.
Sponsor	University Medical Centre Ljubljana
Conditions studied	Polycystic Ovary Syndrome, Body Weight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02941445 ↗